Contact Us

clinical trial

Home
Blog Standard
Tag: clinical trial
Page 2
Company News October 10, 2023 Oxford Vacmedix Comments: 0

New publication highlights importance of survivin as target and potential for combination use to treat cancer

A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of vaccines to treat cancer announced today the publication of a key research paper on its lead cancer vaccine,  OVM-200. The...
Read More
Company News May 26, 2023 Oxford Vacmedix Comments: 0

Oxford Vacmedix feature in ‘Advancing Immunology’

Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the need for invasive treatments such as chemotherapy and radiotherapy for some cancers in future. Watch Oxfo...
Read More
Company News September 8, 2022 Oxford Vacmedix Comments: 0

OVM-200 Phase 1 Clinical Trial featured on TV

The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder of OVM said: We see the potential benefits of a vaccination approach both in stimulating the body’s immune system to attack the...
Read More
Publications
May 11, 2022 Oxford Vacmedix Comments: 0

Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines

From the eradication of smallpox through to the global response to the COVID-19 pandemic, vaccines have been a cornerstone in the fight against infectious diseases in humans and livestock since the 18th century. Although vaccines against COVID-19 are unlikely to eradicate the disease in the way that the smallpox vaccine did, they have proved very effective in preventing death and hospitalisation, with enormous societal and economic benefits. There is now considerable research effort invested in...
Read More
Company News November 4, 2021 Oxford Vacmedix Comments: 0

First patient treated with novel Cancer Vaccine

A Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has started – the first clinical trial of a cancer vaccine using the novel technology. Press Release – Oxford group announces first patient treated with novel cancer vaccine Oxford, 4th November 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the start of a Phase 1 trial of OVM-200 with the first patient being treated at the prestigious Sarah...
Read More
Company News
June 14, 2021 Oxford Vacmedix Comments: 0

Mark Thomas appointed as Head of Clinical Operations

Oxford Vacmedix UK Ltd announces the appointment of Mark Thomas as Head of Clinical Operations, bringing in-depth expertise in running clinical trials and in pharmaceutical development to Oxford Vacmedix. Press Release – appointment of Mark Thomas as Head of Clinical Operations Oxford, 14th June 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mark Thomas as the Head of Clinical Operations. He was previou...
Read More
en_GBEnglish
en_GBEnglish